Back to resultsA Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma
Primary Purpose
Glaucoma, Angle-Closure, Ocular Hypertension
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Travoprost (0.004%)
Latanoprost (0.005%)
Sponsored by
About this trial
This is an interventional treatment trial for Glaucoma, Angle-Closure focused on measuring Glaucoma, POAG, OAG, OHT
Eligibility Criteria
Adult patients of any race and either sex with chronic angle-closure glaucoma.
Sites / Locations
- Asia
- Australia
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00051181
Brief Title
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma
Official Title
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma.
Study Type
Interventional
2. Study Status
Record Verification Date
August 2008
Overall Recruitment Status
Completed
Study Start Date
January 2000 (undefined)
Primary Completion Date
June 2003 (Actual)
Study Completion Date
June 2003 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Alcon Research
4. Oversight
5. Study Description
Brief Summary
To demonstrate that the intraocular pressure(IOP)-lowering efficacy of Travoprost (0.004%) is equal or better than that of Latanoprost 0.005% in patients with chronic angle-closure glaucoma.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glaucoma, Angle-Closure, Ocular Hypertension
Keywords
Glaucoma, POAG, OAG, OHT
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Travoprost (0.004%)
Intervention Type
Drug
Intervention Name(s)
Latanoprost (0.005%)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Adult patients of any race and either sex with chronic angle-closure glaucoma.
Facility Information:
Facility Name
Asia
City
Fort Worth
State/Province
Texas
Country
United States
Facility Name
Australia
City
Sidney
Country
Australia
12. IPD Sharing Statement
Learn more about this trial
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma
We'll reach out to this number within 24 hrs